

CLINICAL TRIAL SUMMARY DESCRIPTION

TITLE: Epirubicin (Ellence) for Advanced Soft Tissue Sarcoma

OBJECTIVE OF STUDY: Phase II trial to study the effectiveness of Epirubicin hydrochloride in treatment of advanced soft tissue sarcoma

MINIMUM ELIGIBILITY REQUIREMENTS: Patients age 18 and over, no history of other malignancy, no other serious medical/psychiatric illness

PARTICIPANT ACTIVITIES (*office visits, tests, take medications, etc*): Patients will receive continuous infusion epirubicin over 48 hours q 21 days x 6 cycles – dosage will be increased as tolerated

CONTACT INFORMATION: **COORDINATOR / CHAIR** (*please circle one*)

NAME/TITLE: Dr. Robert N. Taub, Ph.D.

AFFILIATION: Herbert Irving Comprehensive Cancer Center

MAILING ADDRESS: New York, NY USA

PHONE: 212.305.4076

Email ADDRESS:

WEBSITE (*for complete info*): <http://www.ccc.columbia.edu/>